Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorPromedon

About this trial

This prospective, multi center cohort trial aims to evaluate the efficacy and safety of hysteropexy using Splentis via the vaginal route in primary uterine prolapse

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

non-fertile women

primary symptomatic uterine descent POP-Q≥2

Scheduled apical POP repair with Splentis

Willing and able to participate at study visits and to sign informed consent

Disqualifiers

Fertile women

Recurrent apical prolapse

Women with post hysterectomy vaginal vault prolapse

Patients with active or latent infection of the vagina, cervix or uterus

Trial population

Non-fertile women ≥ 18 years with uterine prolapse

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Splentis® POP Tissue Anchoring System

    Device

    Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis

Treatment groups

140 Participants
are divided into 1 treatment group
Group A: Hysteropexy using Splentis via vaginal route1 intervention

Trial outcomes

Primary outcomes

1

Cure of apical pelvic organ prolapse

Cure of apical pelvic organ prolapse is defined according the current recommendations by Barber et al. and ICS/IUGA recommendations. Therefore, a combined endpoint using anatomical, subjective and necessity retreatment criteria are utilized. Primary endpoint is the number of patients achieving all criteria of the composite endpoint: 1. leading edge of the apical vaginal wall at or above the hymen (C≤ 0) 2. absence of a vaginal bulge symptom 3. no need for retreatment of the apical prolapse by either pessary use or surgical intervention

Time frame
12 months

Secondary outcomes

1

Health-related quality of life

Change of Quality of life and prolapse symptoms using the Prolapse-Quality of Life-Questionnaire in comparison between baseline and follow-up. The questionnaire is divided in nine domains which are analyzed separately. The results will be transformed into a scale between 0 - 100 according the questionnaires description. The higher the score, the higher the impact of prolapse symptoms and the lower the quality of life.

Time frame
Baseline, 6 weeks 12, 24, 36, 60 months
2

Quality of life

Change of quality of life using the EQ-5L-5D in comparison between baseline and follow-up. It consists of a 5-item descriptive system as well as a visual analogue scale ranging from 0 to 100. It is conceptualized to assess deviation from health and hereby provide health related quality of life problems.

Time frame
Baseline, 6 weeks and 12, 24, 36, 60 months
3

Urinary incontinence

Change of urinary incontinence using the International Consultation on Incontinence Questionnaire- Urinary Incontinence Short From in comparison between baseline and follow-up The ICIQ-UI-SF includes four items with a sum score ranging between 0 and 21 points. The higher the score the higher the impact of symptoms.

Time frame
Baseline, 6 weeks and 12, 24, 36, 60 months
4

Overactive Bladder

Change of urinary incontinence using the International Consultation on Incontinence Questionnaire- Overactive bladder in comparison between baseline and follow-up The score of the ICIQ-OAB ranges from 0 to 16 points. The higher the sum score the higher the impact of symptoms.

Time frame
Baseline, 6 weeks and 12, 24, 36, 60 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.